FrancophonIA/ELRC3.0 huggingface dataset:
English: • you have had problems with your liver before, including hepatitis B or C. Your doctor may evaluate how severe your liver disease is before deciding if you can take this medicine.
Croatian: Liječnik će možda procijeniti težinu bolesti jetre prije nego odluči možete li uzimati ovaj lijek.
English: Aluminium and magnesium containing antacids reduce raltegravir plasma levels.
Croatian: Antacidi koji sadrže aluminij i magnezij snižavaju koncentraciju raltegravira u plazmi.
English: • The active substances are lamivudine and raltegravir.
Croatian: • Djelatne tvari su lamivudin i raltegravir.
English: However, unless the patient has renal impairment, no dosage adjustment of DUTREBIS is necessary (see section 4.2).
Croatian: Međutim, nije potrebno prilagođavati dozu lijeka DUTREBIS, osim ako bolesnik nema oštećenje funkcije bubrega (vidjeti dio 4.2).
English: The SWITCHMRK 1 & 2 (Protocols 032 & 033) studies evaluated HIV-infected patients receiving suppressive (screening HIV RNA < 50 copies/ml; stable regimen > 3 months) therapy with lopinavir 200 mg (+) ritonavir 50 mg 2 tablets twice daily plus at least 2 nucleoside reverse transcriptase inhibitors and randomized them 1:1 to continue lopinavir (+) ritonavir 2 tablets twice daily (n=174 and n=178, respectively) or replace lopinavir (+) ritonavir with raltegravir 400 mg twice daily (n=174 and n=176, respectively).
Croatian: Bolesnici su u omjeru 1:1 randomizirani u skupinu koja je nastavila primati lopinavir (+) ritonavir, 2 tablete dvaput na dan (n=174 odnosno n=178), ili u skupinu u kojoj je lopinavir (+) ritonavir zamijenjen raltegravirom u dozi od 400 mg dvaput na dan (n=174 odnosno n=176).
English: • muscle pain and discomfort, joint pain
Croatian: • bol i nelagoda u mišićima, bol u zglobovima
English: CART has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
Croatian: Kombinirana antiretrovirusna terapija povezuje se s metaboličkim poremećajima poput hipertrigliceridemije, hiperkolesterolemije, rezistencije na inzulin, hiperglikemije i hiperlaktatemije
English: Lactic acidosis, usually associated with hepatomegaly and hepatic steatosis, has been reported with the use of nucleoside reverse transcriptase inhibitors (NRTIs), such as lamivudine.
Croatian: Pri primjeni nukleozidnih inhibitora reverzne transkriptaze (NRTI), poput lamivudina, prijavljena je laktacidoza obično udružena s hepatomegalijom i steatozom jetre.
English: Clinical studies in patients have not been specifically performed with DUTREBIS.
Croatian: Nisu provedena posebna klinička ispitivanja lijeka DUTREBIS s bolesnicima.
English: A reduction in renal function may necessitate switching DUTREBIS to a regimen of the individual components (lamivudine and raltegravir).
Croatian: Smanjenje funkcije bubrega može uvjetovati prelazak s lijeka DUTREBIS na režim liječenja njegovim pojedinačnim komponentama (lamivudinom i raltegravirom).
English: The clinical relevance of such findings remains,
Croatian: Međutim kliničko značenje ovog nalaza nije
English: Grade 2-4 creatine kinase laboratory abnormalities were observed in subjects treated with raltegravir.
Croatian: U ispitanika koji su liječeni raltegravirom opažena su odstupanja u laboratorijskim nalazima kreatin kinaze 2. do 4. stupnja.
English: • chest discomfort; chills; swelling of face; feeling jittery; lump in the neck; swelling of
Croatian: • osjećaj nelagode u prsima; zimica; oticanje lica; osjećaj treme; stvaranje nakupine tkiva na vratu; oticanje šaka, gležnjeva ili stopala; bol
English: If creatinine clearance decreases to <50 ml/min, DUTREBIS should be switched to a regimen of the individual components (lamivudine and raltegravir).
Croatian: Ako klirens kreatinina padne na <50 ml/min, DUTREBIS se mora zamijeniti režimom liječenja njegovim pojedinačnim komponentama (lamivudinom i raltegravirom).
English: DUTREBIS must be used in combination with other
Croatian: DUTREBIS se mora uzimati u kombinaciji s drugim lijekovima za liječenje HIV-a.
English: Please refer to the SmPC for the individual components of DUTREBIS for dosing instructions.
Croatian: Za upute o doziranju, pročitajte Sažetke opisa svojstava lijeka pojedinačnih komponenti lijeka DUTREBIS.
English: Refer to the chewable tablet and granules for oral suspension SmPCs
Croatian: Za dodatne informacije o doziranju, pročitajte Sažetke opisa svojstava lijeka za tabletu za žvakanje i granule za oralnu suspenziju.
English: No dose adjustment required for DUTREBIS or boceprevir.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS ili boceprevira.
English: No dosage adjustment for DUTREBIS is required for patients with mild to moderate hepatic impairment.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS u bolesnika s blagim do umjerenim oštećenjem funkcije jetre.
English: No dose adjustment required for DUTREBIS or methadone.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS ili metadona.
English: Interaction not studied calcium carbonate antacid /raltegravir (raltegravir 400 mg Twice Daily)
Croatian: SEDATIV midazolam/raltegravir (raltegravir 400 mg dvaput na dan)
English: Zidovudine has no effect on the pharmacokinetics of lamivudine (see section 5.2).
Croatian: Zidovudin ne utječe na farmakokinetiku lamivudina
English: Mitochondrial dysfunction
Croatian: Oštećenje funkcije bubrega
English: Elderly
Croatian: Crnci
English: No dosage adjustment for DUTREBIS is required for patients with mild to moderate hepatic insufficiency.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS u bolesnika s blagom do umjerenom insuficijencijom jetre.
English: Percent HIV-RNA < 50 copies/ml (95 % CI)
Croatian: Postotak s < 50 HIV-RNK kopija/ml
English: Breastfeeding is not recommended while taking DUTREBIS.
Croatian: Za vrijeme uzimanja lijeka DUTREBIS dojenje se ne preporučuje.
English: Treatment with DUTREBIS should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis
Croatian: Pojave li se klinički znakovi, simptomi ili odstupanja u laboratorijskim nalazima koja upućuju na pankreatitis, liječenje lijekom DUTREBIS
English: MSD Pharma Hungary Kft. Tel.: +361 888 53 00 hungary_msd@merck.com
Croatian: Tel.: +361 888 53 00 hungary_msd@merck.com
English: Myopathy and rhabdomyolysis have been reported with raltegravir.
Croatian: Pri primjeni raltegravira prijavljene su miopatija i rabdomioliza.
English: (chelation of metal cations)
Croatian: (povećana topljivost)
English: raltegravir AUC  55 % raltegravir C12 hr  32 % raltegravir Cmax  52 %
Croatian: raltegravir AUC  24% raltegravir C12h  55% raltegravir Cmax  18%
English: Frequency Lamivudine and/or Raltegravir (alone or in combination with other ART)* uncommon genital herpes, folliculitis, gastroenteritis, herpes simplex, herpes virus infection, herpes zoster, influenza, lymph node abscess, molluscum contagiosum, nasopharyngitis, upper respiratory tract uncommon iron deficiency anaemia, lymph node pain, lymphadenopathy, neutropenia and anaemia (both occasionally severe),
Croatian: manje često genitalni herpes, folikulitis, gastroenteritis, herpes simplex, infekcija virusom herpesa, herpes zoster, influenca, apsces limfnih čvorova, mollusca contagiosa, nazofaringitis, infekcije gornjeg manje često sideropenična anemija, bol u limfnom čvoru, limfadenopatija,
English: Talk to your doctor, pharmacist or nurse immediately if you experience unexplained muscle pain, tenderness or weakness while taking this medicine.
Croatian: Ako tijekom uzimanja ovog lijeka osjetite bol, osjetljivost ili slabost u mišićima nepoznatog uzroka, odmah se obratite svom liječniku, ljekarniku ili medicinskoj sestri.
English: However, if co-administration with rifampicin is unavoidable, DUTREBIS may be switched to a regimen of the individual components (lamivudine and raltegravir).
Croatian: Međutim, ako je istodobna primjena s rifampicinom neizbježna, može se prijeći na režim liječenja pojedinačnim komponentama lijeka DUTREBIS (lamivudinom i raltegravirom).
English: Cancers were reported in treatment-experienced and treatment-naïve patients who initiated raltegravir in conjunction with other antiretroviral agents.
Croatian: U prethodno liječenih i neliječenih bolesnika koji su započeli liječenje raltegravirom u kombinaciji s drugim antiretrovirusnim lijekovima prijavljeni su slučajevi raka.
English: The true extent of penetration or relationship with any clinical efficacy is unknown.
Croatian: Nije poznat pravi razmjer prolaska niti povezanost s
English: There is little to no accumulation in AUC and Cmax and evidence of slight accumulation in C12 hr.
Croatian: Kumulacija u AUC i Cmax je mala ili je nema, a opažena je
English: No study has been performed with DUTREBIS in subjects with hepatic insufficiency.
Croatian: Nije provedeno ispitivanje lijeka DUTREBIS u ispitanika s insuficijencijom jetre.
English: /sulfamethoxazole is necessary, unless the patient has renal impairment (see section 4.2).
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS ili trimetoprima/sulfametoksazola, osim ako bolesnik nema oštećenje funkcije bubrega (vidjeti dio 4.2).
English: Vistor hf.
Croatian: "EXP".
English: Pharmacotherapeutic group: Antivirals for systemic use; antivirals for treatment of HIV infections,
Croatian: Farmakoterapijska skupina: Pripravci za liječenje sustavnih virusnih infekcija, antivirotici za terapiju HIV-a, kombinacije, ATK oznaka: J05AR16.
English: Metabolism and nutrition disorders common decreased appetite uncommon cachexia, diabetes mellitus, dyslipidaemia, hypercholesterolaemia, hyperglycaemia, hyperlipidaemia, hyperphagia, increased appetite, polydipsia, body fat disorder
Croatian: manje često kaheksija, diabetes mellitus, dislipidemija, hiperkolesterolemija, hiperglikemija, hiperlipidemija, hiperfagija, pojačan apetit, polidipsija, poremećaj masnog tkiva neuobičajeni snovi, insomnia, noćne more, neuobičajeno ponašanje,
English: Therefore, co-administration of DUTREBIS with aluminium and/or magnesium containing antacids is not recommended.
Croatian: Iz toga se razloga istodobna primjena lijeka DUTREBIS s antacidima koji sadrže aluminij i/ili magnezij ne preporučuje.
English: Therefore no dose adjustment of DUTREBIS is required.
Croatian: Stoga nije potrebno prilagođavati dozu lijeka DUTREBIS.
English: Psychiatric disorders common abnormal dreams, insomnia, nightmare, abnormal behaviour, depression uncommon mental disorder, suicide attempt, anxiety, confusional state, depressed mood, major depression, middle insomnia, mood altered, panic attack, sleep disorder, suicidal ideation, suicidal behaviour (particularly in patients with a pre-existing history of psychiatric illness)
Croatian: manje često mentalni poremećaj, pokušaj suicida, anksioznost, stanje konfuzije, depresivno raspoloženje, teška depresija, umjerena insomnia, promjena raspoloženja, napadaj panike, poremećaj spavanja, suicidalne ideacije, suicidalno ponašanje (osobito u bolesnika s psihijatrijskom bolešću u anamnezi) omaglica, glavobolja, psihomotorička hiperaktivnost manje često amnezija, sindrom karpalnog kanala, kognitivni poremećaj, poremećaj pažnje, posturalna omaglica, disgeuzija, hipersomnija, hipoestezija, letargija, poremećaj pamćenja, migrena, periferna neuropatija, parestezija, somnolencija, tenzijska glavobolja, tremor,
English: Tablet core
Croatian: Ispitivanje STARTMRK
English: If co-administration with rifampicin is unavoidable, DUTREBIS may be switched to a regimen of the individual components (lamivudine and raltegravir).
Croatian: Ako je istodobna primjena s rifampicinom neizbježna, može se prijeći na režim liječenja pojedinačnim komponentama lijeka DUTREBIS (lamivudinom i raltegravirom).
English: zidovudine Cmax  28 % zidovudine AUC ↔
Croatian: midazolam AUC  8% midazolam Cmax ↑ 3%
English: The exposure-adjusted rates of rash (all causality) were 10.9, 4.2, and 3.8 per 100 patient-years (PYR), respectively; and for drug-related rash were 2.4, 1.1, and 2.3 per 100 PYR, respectively.
Croatian: Stope učestalosti osipa (bilo kojeg uzroka) prilagođene s obzirom na izloženost iznosile su 10,9 na 100 bolesnik-godina u bolesnika koji su primali raltegravir + darunavir, 4,2 na 100 bolesnik-godina u bolesnika koji su primali raltegravir bez darunavira i 3,8 na 100 bolesnik-godina u bolesnika koji su primali darunavir bez raltegravira; dok su za osip povezan s lijekom, stope učestalosti u te tri skupine iznosile 2,4; 1,1 odnosno 2,3 na 100 bolesnik-godina.
English: Frequency Lamivudine and/or Raltegravir (alone or in combination with other ART)* tissue disorders uncommon acne, dermatitis acneiforme, dry skin, erythema, facial wasting, hyperhidrosis, lipoatrophy, lipodystrophy acquired, lipohypertrophy, night sweats, prurigo, pruritus, pruritus generalised, rash macular, rash maculo-papular, rash pruritic, skin lesion, urticaria, xeroderma, Stevens Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS)
Croatian: Poremećaji probavnog sustava često distenzija abdomena, dijareja, flatulencija, mučnina, povraćanje, dispepsija, bol ili grčevi u abdomenu manje često gastritis, nelagoda u abdomenu, bol u gornjem abdomenu, osjetljivost abdomena, nelagoda u anorektalnom području, konstipacija, suha usta, nelagoda u epigastriju, erozivni duodenitis, eruktacija, gastroezofagealna refluksna bolest, gingivitis, glositis, odinofagija, pankreatitis, peptički ulkus, krvarenje iz rektuma manje često hepatitis, hepatička steatoza, alkoholni hepatitis, zatajenje jetre manje često akne, akneiformni dermatitis, suha koža, eritem, gubitak potkožnog masnog tkiva lica, hiperhidroza, lipoatrofija, stečena lipodistrofija, lipohipertrofija, noćno znojenje, prurigo, pruritus, generalizirani pruritus, makularni osip, makulopapularni osip, osip s pruritusom, kožne lezije, urtikarija, kseroderma, Stevens-Johnsonov sindrom, osip izazvan lijekom uz eozinofiliju i sustavne simptome (DRESS)
English: Rare (may affect up to 1 in 1,000 people) • serious allergic reaction causing swelling of the face, tongue or throat which may cause
Croatian: • ozbiljna alergijska reakcija koja uzrokuje oticanje lica, jezika ili grla, što može otežati gutanje ili disanje
English: CZ
Croatian: C.
English: Paediatric population
Croatian: Svi bolesnici
English: • joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty moving.
Croatian: Obavijestite svog liječnika ako primijetite neki od sljedećih znakova osteonekroze: • ukočenost zglobova, bolovi u zglobovima (osobito u kuku, koljenu i ramenu) i poteškoće pri
English: Carton
Croatian: Kutija
English: Two components, namely raltegravir and raltegravir-glucuronide, were detected in urine and accounted for approximately 9 and 23 % of the dose, respectively.
Croatian: Raltegravir je predstavljao oko 9%, a raltegravir-glukuronid oko 23% doze.
English: IT
Croatian: IE
English: • pain in the upper part of the belly; rectal discomfort; constipation; dry mouth; heartburn; pain when swallowing; inflammation of the pancreas (pancreatitis); ulcer or sore in stomach or upper intestine; bleeding from anus; stomach discomfort; inflammation of the
Croatian: (rektuma); zatvor; suha usta; žgaravica; bol pri gutanju; upala gušterače (pankreatitis); čir ili ranice u želucu ili gornjem dijelu crijeva; krvarenje iz čmara (anusa); osjećaj nelagode u želucu; upala zubnog mesa; natečen, crven i bolan jezik
English: Raltegravir was not teratogenic in developmental toxicity studies in rats and rabbits.
Croatian: U istraživanjima razvojne toksičnosti na štakorima i kunićima raltegravir se nije pokazao teratogenim.
English: No dosage adjustment required for DUTREBIS or midazolam.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS ili midazolama.
English: One pack size is
Croatian: • smanjen tek
English: If rifampicin administration cannot be avoided, DUTREBIS may be switched to a regimen of the individual components (lamivudine and raltegravir).
Croatian: Ako je primjena rifampicina neizbježna, može se prijeći na režim liječenja pojedinačnim komponentama lijeka DUTREBIS (lamivudinom i raltegravirom).
English: No dose adjustment required for DUTREBIS.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS.
English: • liver problems, such as yellowing of the skin or whites of the eyes, swollen or fatty liver • blood test showing an increase in an enzyme called amylase
Croatian: • jetrene tegobe, poput žute boje kože ili bjeloočnica, otečene ili masne jetre
English: • taking drug in quantities greater than recommended These are rare (may affect up to 1 in 1,000 people)
Croatian: Ove su nuspojave rijetke (mogu se javiti u do 1 na 1000 osoba):
English: Mean CD4 cell count (%) increase from baseline
Croatian: Srednja vrijednost promjene broja CD4 stanica (95% CI), stanica/mm
English: Tell your doctor, pharmacist or nurse immediately if you notice any symptoms of infection, such
Croatian: Odmah obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako primijetite bilo koji
English: This study enrolled
Croatian: Tablični popis nuspojava
English: 6 hours after raltegravir raltegravir AUC  11 % raltegravir C12 hr  49 % raltegravir Cmax  10 %
Croatian: raltegravir AUC ↑ 44% raltegravir C12h ↑ 6% raltegravir Cmax ↑ 60%
English: Pharmacokinetics in pregnancy
Croatian: Prethodno liječeni odrasli bolesnici
English: atazanavir /ritonavir /lamivudine Interaction not studied
Croatian: atazanavir/ritonavir/lamivudin Interakcija nije ispitana. tipranavir/ritonavir/raltegravir (raltegravir 400 mg dvaput na dan)
English: No dosage adjustment is necessary for DUTREBIS based on age.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS prema dobi.
English: Physicians should refer to current HIV treatment guidelines for the optimal management of HIV infection in patients co-infected with HBV.
Croatian: Radi optimalnog zbrinjavanja HIV infekcije u bolesnika koji su istodobno inficirani virusom hepatitisa B, liječnici moraju slijediti važeće smjernice za liječenje HIV-a.
English: Skin and subcutaneous common rash, alopecia
Croatian: • osip, gubitak kose (alopecija)
English: zidovudine /raltegravir
Croatian: Klinička djelotvornost raltegravira
English: CART has been associated with the redistribution of body fat (lipodystrophy) in HIV patients.
Croatian: U bolesnika inficiranih HIV-om se kombinirana antiretrovirusna terapija povezuje s preraspodjelom masnog tkiva u tijelu (lipodistrofija).
English: The medicine is given once every 12 hours for at least 4 days and up to 14 days.
Croatian: Lijek se primjenjuje svakih 12 sati u trajanju od najmanje 4, a najviše 14 dana.
English: Xerava (eravacycline)
Croatian: Xerava (eravaciklin)
English: Further information on Xerava can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Xerava nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This leads to death of the bacteria causing the infection.
Croatian: To dovodi do smrti bakterija koje uzrokuju infekciju.
English: The main measure of effectiveness in both studies was whether the infection was cured.
Croatian: Glavno mjerilo djelotvornosti u objema studijama bila je uspješnost izlječenja infekcije.
English: Xerava (eravacycline) EMA/521584/2018
Croatian: Xerava (eravaciklin) EMA/521584/2018
English: Xerava's safety profile was considered acceptable.
Croatian: Sigurnosni profil lijeka Xerava smatra se prihvatljivim.
English: The dose depends on the patient's bodyweight, and may be increased if the patient is also taking a type of medicine called a ‘strong CYP3A4 inducer'.
Croatian: Doza ovisi o tjelesnoj težini bolesnika, a može se povećati ukoliko bolesnik također uzima i vrstu lijeka koji je „jaki induktor CYP3A4“.
English: The most common side effects with Xerava (which may affect up to 1 in 10 people) are thrombophlebitis (inflammation of veins caused by a blood clot), phlebitis (inflammation of a vein), nausea (feeling sick), vomiting and reactions at the site of the infusion including reddening of skin, reduced sense of touch and pain.
Croatian: Najčešće nuspojave lijeka Xerava (koje mogu utjecati na 1 do 10 osoba) su tromboflebitis (upala vena uzrokovana krvnim ugruškom), flebitis (upala vena), mučnina (slabost), povraćanje i reakcije na mjestu primjene infuzije, uključujući crvenilo kože i smanjeni osjećaj dodira i boli.
English: What measures are being taken to ensure the safe and effective use of Xerava?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Xerava?
English: Other information about Xerava
Croatian: Ostale informacije o lijeku Xerava
English: What are the risks associated with Xerava?
Croatian: Koji su rizici povezani s lijekom Xerava?
English: Why is Xerava authorised in the EU?
Croatian: Zašto je lijek Xerava odobren u EU-u?
English: Therefore the European Medicines Agency decided that Xerava's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove stoga je zaključila da koristi od lijeka Xerava nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: What is Xerava and what is it used for?
Croatian: Što je Xerava i za što se primjenjuje?
English: Side effects reported with Xerava are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Xerava pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xerava have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Xerava nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Xerava must not be used in patients who are hypersensitive (allergic) to any of the ingredients of the medicine or to other tetracycline antibiotics.
Croatian: Xerava se ne smije koristiti u bolesnika koji su preosjetljivi (alergični) na bilo koji od sastojaka lijeka ili na druge tetraciklinske antibiotike.
English: Xerava is given by infusion (drip) into a vein over one hour.
Croatian: Xerava se primjenjuje intravenskom infuzijom (nakapavanje) u trajanju od jednoga sata.
English: Xerava is as effective as alternative antibiotics in treating infections caused by various types of bacteria and produced high cure rates.
Croatian: Lijek Xerava jednako je učinkovit kao i alternativni antibiotici u liječenju infekcija uzrokovanih raznim vrstama bakterija i ima visoku stopu izlječenja.
English: After around a month, 87% of patients treated with Xerava were cured of their infection, compared to 89% of patients treated with ertapenem.
Croatian: Nakon približno mjesec dana, 87 % bolesnika liječenih Xeravom izliječeno je od infekcije, u usporedbi s 89 % bolesnika liječenih ertapenemom.
English: An overview of Xerava and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Xerava i zašto je odobren u EU-u
English: After around a month, 92% of patients treated with Xerava and 92% of patients treated with meropenem were cured of their infection.
Croatian: Nakon približno mjesec dana, 92 % bolesnika liječenih Xeravom i 92 % bolesnika liječenih meropenemom izliječeno je od infekcije.
English: As for all medicines, data on the use of Xerava are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Xerava kontinuirano se prate.
English: The active substance in Xerava, eravacycline, belongs to a group of antibiotics called tetracyclines.
Croatian: Djelatna tvar u lijeku Xerava, eravaciklin, pripada skupini antibiotika nazvanih tetraciklini.
English: Xerava can only be obtained with a prescription and prescribers should take into account official guidance on the use of antibiotics.
Croatian: Xerava se izdaje samo na liječnički recept recept, a liječnici koji propisuju lijek trebaju uzeti u obzir službene smjernice o primjerenoj upotrebi antibiotika.